{
  "id": "9af2158e04c77c82",
  "title": "Biotech - Knaller aus den united states : Brustkrebs - Impfstoff : Phase 1 gelingt - 74 % Immunantworten , Phase 2 r\u00fcckt n\u00e4her",
  "description": "20251212T083000Z",
  "content": "",
  "source": "finanznachrichten.de",
  "source_url": "https://www.finanznachrichten.de/nachrichten-2025-12/67215562-biotech-knaller-aus-den-usa-brustkrebs-impfstoff-phase-1-gelingt-74-immunantworten-phase-2-rueckt-naeher-669.htm",
  "published_at": "20251212T083000Z",
  "fetched_at": "2025-12-13T00:21:55.936102+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [],
  "location": "Germany",
  "raw_data": {
    "url": "https://www.finanznachrichten.de/nachrichten-2025-12/67215562-biotech-knaller-aus-den-usa-brustkrebs-impfstoff-phase-1-gelingt-74-immunantworten-phase-2-rueckt-naeher-669.htm",
    "url_mobile": "",
    "title": "Biotech - Knaller aus den united states : Brustkrebs - Impfstoff : Phase 1 gelingt - 74 % Immunantworten , Phase 2 r\u00fcckt n\u00e4her",
    "seendate": "20251212T083000Z",
    "socialimage": "https://www.finanznachrichten.de/chart-anixa-biosciences-inc-aktie-intraklein-tradegate.png",
    "domain": "finanznachrichten.de",
    "language": "German",
    "sourcecountry": "Germany"
  }
}